Search Results - "De Toni, E."

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects by Tang, Weiwei, Chen, Ziyi, Zhang, Wenling, Cheng, Ye, Zhang, Betty, Wu, Fan, Wang, Qian, Wang, Shouju, Rong, Dawei, Reiter, F. P., De Toni, E. N., Wang, Xuehao

“…Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis and suppressing tumor cell proliferation. In late-stage…”
Get full text

The role of the novel Th17 cytokine IL-26 in intestinal inflammation by Dambacher, J, Beigel, F, Zitzmann, K, De Toni, E N, Göke, B, Diepolder, H M, Auernhammer, C J, Brand, S

“…Interleukin 26 (IL-26), a novel IL-10-like cytokine without a murine homologue, is expressed in T helper 1 (Th1) and Th17 cells. Currently, its function in…”
Get more information

Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling by Ischenko, I, Camaj, P, Seeliger, H, Kleespies, A, Guba, M, De Toni, E N, Schwarz, B, Graeb, C, Eichhorn, M E, Jauch, K-W, Bruns, C J

“…Resistance to chemotherapy is believed to be a major cause of treatment failure in pancreatic cancer. Thus, it is necessary to explore alternative therapeutic…”
Get full text

STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma by Marozin, S, Altomonte, J, Muñoz-Álvarez, K A, Rizzani, A, De Toni, E N, Thasler, W E, Schmid, R M, Ebert, O

“…Hepatocellular carcinoma (HCC) is a refractory malignancy with a high mortality and increasing worldwide incidence rates, including the United States and…”
Get full text

JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand by Mucha, S R, Rizzani, A, Gerbes, A L, Camaj, P, Thasler, W E, Bruns, C J, Eichhorst, S T, Gallmeier, E, Kolligs, F T, Göke, B, De Toni, E N

“…cJun terminal kinase (JNK) is constitutively activated in most hepatocellular carcinomas (HCCs), yet its exact role in carcinogenesis remains controversial…”
Get more information

Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study by Ertl, C., Ruf, T., Hammann, L., Piseddu, I., Wang, Y., Schmitt, C., Garza Vazquez, X., Kabakci, C., Bonczkowitz, P., de Toni, E.N., David-Rus, R., Srour, J., Tomsitz, D., French, L.E., Heinzerling, L.

“…Checkpoint inhibitor-induced steroid-refractory (sr) and steroid-dependent (sd) immune-related adverse events (irAE) account for about 11 % of irAE. Although…”
Get full text

Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients by Paprottka, K. J., Schoeppe, F., Ingrisch, M., Rübenthaler, J., Sommer, N. N., De Toni, E., Ilhan, H., Zacherl, M., Todica, A., Paprottka, P. M.

“…Purpose To determine pre-therapeutic predictive factors for overall survival (OS) after yttrium (Y)-90 radioembolization (RE). Methods We retrospectively…”
Get full text

The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The SORAMIC trial palliative cohort by Ricke, J., Sangro, B., Amthauer, H., Bargellini, I., Bartenstein, P., De Toni, E., Gasbarrini, A., Klumpen, H J, Peck, M., Popovic, P., Rosmorduc, O., Schott, E., Verslype, C., Malfertheiner, P.

Get full text

The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells by Zitzmann, Kathrin, De Toni, Enrico N, Brand, Stephan, Göke, Burkhard, Meinecke, Jennifer, Spöttl, Gerald, Meyer, Heinrich H D, Auernhammer, Christoph J

“…Tumors exhibiting constitutively activated PI(3)K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being…”
Get more information

955P IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma by Vogel, A., Saborowski, A., Siegler, G.M., Siebler, J., Lindig, U., Schultheiss, M., Mueller, T., Simon, H., Jöckel, C., Müller, D.W., Al-Batran, S-E., De Toni, E.

Get full text

LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) by Vogel, A., Saborowski, A., Hinrichs, J., Ettrich, T.J., Ehmer, U., Martens, U.M., Mekolli, A., De Toni, E., Berg, T., Geißler, M., Maenz, M., Kirstein, M., Waldschmidt, D.

Get full text

Haemolysis during cardiopulmonary bypass: how to reduce the free haemoglobin by managing the suctioned blood separately by Pierangeli, A, Masieri, V, Bruzzi, F, De Toni, E, Grillone, G, Boni, P, Delnevo, A

“…During cardiopulmonary bypass (CPB) the collection of the patient’s blood from the operating area is of fundamental importance. This blood is collected in the…”
Get full text

SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma by Sangro, B., Chan, S., Kelley, R., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., De Toni, E., Furuse, J., Kang, Y., Galle, P., Rimassa, L., Heurgué, A., Tam, V., Dao, T., Thungappa, S., Breder, V., Ostapenko, Y., Reig, M., Makowsky, M., Gupta, C., Negro, A., Abou-Alfa, G.

Get full text

EP-1446: Stereotactic Body Radiotherapy (SBRT) in patients with HCC in a multimodal treatment setting by Gerum, S., Heinz, C., Belka, C., Paprottka, P., De Toni, E., Roeder, F.

Get full text

EP-1412 Excellent pCR rate in patients with HCC after SBRT +/-TACE as bridging to liver transplantation by Gerum, S., Heinz, C., Belka, C., Paprottka, P.M., Neumann, J., De Toni, E., Guba, M., Roeder, F.

Get full text

988P Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC by Vogel, A., Müller, D.W., De Toni, E., Siegler, G.M., Siebler, J., Lindig, U., Müller, T., Schultheiss, M., Geißler, M., Krammer-Steiner, B., Reichart, A., Lammert, F., Prause, C., Walker, M., Al-Batran, S-E., Kosic, N.

Get full text

Purines and pyrimidines determination in urine using high-performance liquid chromatography by Minniti, G, Caruso, U, Cerone, R, de Toni, E

“…Single purine and pyrimidine bases are involved in two fundamental metabolic pathways that lead to formation of the building stones of DNA and RNA. Purine and…”
Get more information

O-029The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The SORAMIC trial palliative cohort by Ricke, J, Sangro, B, Amthauer, H, Bargellini, I, Bartenstein, P, De Toni, E, Gasbarrini, A, Klumpen, H J, Peck, M, Popovic, P, Rosmorduc, O, Schott, E, Verslype, C, Malfertheiner, P

Get full text

The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The Soramic trial palliative cohort by Ricke, J., Sangro, B., Amthauer, H., Bargellini, I., Bartenstein, P., De Toni, E., Gasbarrini, A., Klümpen, H.-J., Peck-Radosavljevic, M., Popovic, P., Rosmorduc, O., Schott, E., Van Buskirk, M., Malfertheiner, P.

Get full text

LBO-005 - The impact of combining Selective Internal Radiation Therapy (SIRT) with Sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The Soramic trial palliative cohort by Ricke, J., Sangro, B., Amthauer, H., Bargellini, I., Bartenstein, P., De Toni, E., Gasbarrini, A., Klümpen, H.-J., Peck-Radosavljevic, M., Popovic, P., Rosmorduc, O., Schott, E., Van Buskirk, M., Malfertheiner, P.

Get full text